Rapport Therapeutics’ RAP-219 delivers statistically significant bipolar mania improvements in Phase 2 trial
Rapport Therapeutics' RAP-219 meets Phase 2 bipolar mania endpoints. Explore its clinical results, safety findings and planned Phase 3 trials.